• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novo Nordisk

335.40 DKK+2.73 %28.7, 17.10
1,055 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.73 %
+5.49 %
+27.29 %
-14.86 %
+3.12 %
-25.81 %
-36.98 %
+19.32 %
+26,839.76 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.5T DKK
Turnover
1.23B DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
14.54
Dividend yield-%
3.49 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
The market is currently paying far too much attention to who has the best percentages in clinical trials. In 5 years, it won’t matter whether the figure is 18%, 23%, or 28%. For the consumer, price will be the deciding factor and other things will be secondary. And since patents ...
6/6/2026, 7:27 PM
by JNivala
65
Boostia Wegovylle uuden myyntiluvan muodossa. First GLP-1 pill approved in the European Union for the treatment of obesity and overweight Novo Nordisk News Details
7/15/2026, 5:40 PM
by Keepitcoming
30
Yep, I’ve been pondering the same thing—why hasn’t this price collapse affected Eli Lilly’s valuation multiples? To a layman’s eye, the new drugs don’t seem so much better that I’d pay significantly more for them. Then again, I’m not the target audience and I don’t understand anything...
6/7/2026, 8:47 AM
by samamies
25
Inderes Novo Nordisk takes action to stop multiple misleading national GLP-1... A lawsuit, filed today in federal court, challenges a nationwide pattern of deceptive advertising which confuses consumers by using outdated studies to compare the highest injectable doses of... Well,...
7/21/2026, 4:48 PM
by JNivala
21
https://www.marketwatch.com/story/the-wegovy-pill-is-still-dominating-the-glp-1-pill-market-f7add507?mod=home_lead Pill sales have gotten off to a nice start. Eli Lilly’s pill sales launched much more sluggishly.
6/8/2026, 6:44 AM
by Kryptoniitti
20
Manufacturing semaglutide is a demanding process, so as I understand it, its price will not drop to the level of aspirin anytime soon. Novo holds a competitive advantage in manufacturing processes and production machinery, allowing them to generate strong profits for a long time—...
6/7/2026, 4:08 PM
by Kari Kokkonen
13
Here is an article from SalkunRakentaja about Novo, a concise piece on Novo Nordisk that can be read in a few minutes. It shouldn’t contain major new information for those following the company closely, but it’s a good overview nonetheless. The market reaction has been twofold. In...
6/20/2026, 6:23 AM
by Sijoittaja-alokas
11
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.8
2026

Interim report Q2'26

4.11
2026

Interim report Q3'26

Regulatory press release27.07.2026, 12.48

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release21.07.2026, 13.35

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly

Novo Nordisk
Regulatory press release20.07.2026, 14.31

Novo Nordisk A/S - share repurchase programme

Novo Nordisk

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release15.07.2026, 17.50

Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved

Novo Nordisk
Regulatory press release13.07.2026, 14.24

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Morgenbørs 10/09: GreenMobility CEO interviewes og Europæiske markeder åbner rødt
Video10.07.2026, 09.20

Morgenbørs 10/09: GreenMobility CEO interviewes og Europæiske markeder åbner rødt

Udsigt til mindre kursfald i Europa fra morgenstunden. Fokus herhjemme på Tryg efter Q2 2026 her til morgen. Gæst i studiet er CEO Kasper Gjedsted fra GreenMobility.

Danske BankFøroya BankiGrønlandsbankenScandinavian Medical SolutionsSP GroupRovsingGreenMobilityNovo NordiskA.P. Møller - Mærsk
Regulatory press release06.07.2026, 12.16

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 06/07 - Fortsat fokus på sektorrotation mod cykliske og defensive aktier
Video06.07.2026, 09.32 by
Victor Skriver, Rasmus Køjborg

HCA Morgenbørs 06/07 - Fortsat fokus på sektorrotation mod cykliske og defensive aktier

I dagens Morgenbørs ser vi ind i en flad til negativ åbning i Europa, hvor der fortsat er fokus på en sektorrotation mod mere cykliske og defensive aktier. Herhjemme er der blandt andet fokus på Novo Nordisk, Carlsberg og North Media.

Novo NordiskColoplastDemantCarlsbergNorth MediaAscelia Pharma
HCA Morgenbørs 02/07 - Udsalg i AI infrastruktur
Video02.07.2026, 09.27 by
Michael Friis, Victor Skriver

HCA Morgenbørs 02/07 - Udsalg i AI infrastruktur

Udsigt til en relativ flad åbning i Europa fra morgenstunden, det trods stort udsalg i asien af AI infrastruktur aktier på Meta historien. Fokus herhjemme på blandt andet B&O, ISS, NKT, Pandora.

Bang & OlufsenNKTNovo NordiskPandoraA.P. Møller - MærskISS
HCA Morgenbørs 30/06 - Udsigt til små kursstigninger i Europa
Video30.06.2026, 10.19 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 30/06 - Udsigt til små kursstigninger i Europa

Udsigt til små kursstigninger i Europa fra morgenstunden efter massiv optur i USA, og et Asien der trækkes op af tech. Fokus herhjemme på bl.a. Mærsk, Boozt, Vestas, Novo

A.P. Møller - MærskBooztVestas Wind SystemsNovo Nordisk
Regulatory press release29.06.2026, 14.10

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 29/06 - Udsigt til kursstigninger og fokus på sektorrotation
Video29.06.2026, 09.16 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 29/06 - Udsigt til kursstigninger og fokus på sektorrotation

Udsigt til kursstigninger i Europa fra morgenstunden, fredagens sektorrotation ud af tech samt mildere toner mellem USA og Iran trækker op. Fokus herhjemme på bl.a. Novo Nordisk, Lundbeck og Carlsberg.

Flügger GroupLundbeckCarlsbergBavarian NordicBioMar GroupNovo NordiskBang & Olufsen
HCA Morgenbørs 25/06 - Europa ser ikke ud til at være inviteret med til aktiefesten
Video25.06.2026, 09.24 by
Victor Skriver, Michael Friis

HCA Morgenbørs 25/06 - Europa ser ikke ud til at være inviteret med til aktiefesten

Europa ser ikke ud til at være inviteret med til aktiefesten resten af verden har med baggrund i Micron regnskabet og faldende oliepriser. herhjemme fokus på Novo, energiaktier

Novo NordiskNKTVestas Wind SystemsFlügger GroupHarboes Bryggeri
Regulatory press release22.06.2026, 14.51

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 22/06 - Fredsprocessen er tilbage på sporet og fokus på Novo og Vestas
Video22.06.2026, 09.28 by
Victor Skriver, Michael Friis

HCA Morgenbørs 22/06 - Fredsprocessen er tilbage på sporet og fokus på Novo og Vestas

Udsigt til en flad åbning i Europa, tegn på fredsproces er tilbage på sporet efter bump hen over weekenden. Herhjemme fokus på blandt andet Novo Nordisk og Vestas

Novo NordiskVestas Wind SystemsFLSmidth & Co.Bavarian NordicNordea
HCA Morgenbørs 19/06 - Udsigt til negative markeder og lavere aktivitet
Video19.06.2026, 09.34 by
William Jørck, Rasmus Køjborg

HCA Morgenbørs 19/06 - Udsigt til negative markeder og lavere aktivitet

TormHafniaBioMar GroupNovo NordiskVestas Wind SystemsBioPortoH+H InternationalDanish Aerospace and Defence Company
HCA Morgenbørs 17/06 - FED rentemøde i fokus
Video17.06.2026, 09.20 by
Rasmus Køjborg, Victor Skriver

HCA Morgenbørs 17/06 - FED rentemøde i fokus

Udsigt til svagt faldende europæiske markeder her til morgen imens US futures peger den anden vej. Fokus herhjemme på bl.a. Novo Nordisk, Zealand Pharma og Maersk.

TormHafniaNovo NordiskZealand PharmaA.P. Møller - MærskScandinavian Medical SolutionsInstallatørGruppenFLSmidth & Co.BioMar GroupBar DjusNKT
HCA Morgenbørs 16/06 - Får vi nu også en åbning af Hormuz?
Video16.06.2026, 09.18 by
Michael Friis, Victor Skriver

HCA Morgenbørs 16/06 - Får vi nu også en åbning af Hormuz?

Flade futures globalt fra morgenstunden, Investorer diskuterer om vi nu også får en åbning af Hormuz fredag og afventede FED. herhjemme fokus på kursmålsændringer på en nyhedsfattig dag.

Novo NordiskZealand PharmaSolarDSVA.P. Møller - MærskAGF
Regulatory press release15.06.2026, 13.02

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release11.06.2026, 17.30

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Novo Nordisk